Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

NCT06069843 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT06069843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06069843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KET-MCI: An Open-label Trial of Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2024
Completion date
September 30, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, mild cognitive impairment